Inhalation

INH1026

Issue link: https://www.e-digitaleditions.com/i/1546950

Contents of this Issue

Navigation

Page 7 of 43

Respiratory Drug Delivery (RDD®) Europe 2027 (www.rddonline.com/ rddeurope2027) will take place in Antibes, France, April 27-30, 2027. Now is the time to nominate speakers, design workshops and develop poster abstracts. 6 OctOber 2026 Inhalation CROSS-INDUSTRY Organizations RDD Conferences—Bringing the pulmonary and nasal world together The Organizers of the Respiratory Drug Delivery Conference Series Respiratory Drug Delivery (RDD ® ) Europe 2027 (www.rddonline.com/ rddeurope2027) will take place in Antibes, France, April 27-30, 2027. Now is the time to nominate speak- ers, design workshops and develop poster abstracts. Before looking ahead, let's recap RDD 2026 (www.rddonline.com/ rdd2026) held in Phoenix, Ari- zona, US, to whet your appetite. It was a highly interactive and informative conference with more than 400 delegates from 23 coun- tries exchanging ideas about the latest science and technology driv- ing inhaled and nasal drug prod- uct development. New exhibitors and fresh faces in the audience explored cutting-edge science with speakers and other delegates during the various networking opportunities. e vibe was ener- getic and inclusive, with themed knowledge spaces connecting people and organizations around shared interests. Highlights from RDD 2026 Drawing on his extensive track record of innovations, Jeffry Weers presented the keynote address, "Implications of the iBCS on Molecule Design and Par- ticle Engineering of Medicines for Inhalation," concluding that the inhalation Biopharmaceutics Classification System provides a valuable framework for develop- ing new delivery systems beyond those traditionally used to treat asthma and COPD. "Disrupt, Repurpose, Deliver" explored the changing inhaled and nasal pipeline with a central message that future success will depend not only on promising molecules, but also on adaptable technology platforms that can sup- port multiple products and devel- opment pathways. Nitesh Kunda and Francesca Buttini exempli- fied the changing landscape with insightful presentations sharing progress in inhaled drug deliv- ery for non-small cell lung cancer and repurposing GLP-1 receptor agonists for pulmonary and nasal delivery. Subsequent sessions explored why "New Molecules Need New Methods" including a translational approach designed to improve prediction of clinical bioavailability as well as develop- ing analytical best practices for respiratory biologics. Jan de Backer chaired the "Data Driven Design in Respiratory Product Development" Explore with Experts Panel, which revis- ited the case for connected inhal- ers, the growing role of in silico modeling, artificial intelligence and US Food and Drug Administration (FDA) regulatory acceptance of these advanced approaches. Addi- tional sessions examined "Design- ing Intranasal Delivery Systems for Deposition, Retention, and Scale" to support commercial success as well as "Next- Generation DPI erapies" focused on development of "Powders at Perform," which included a presentation by the FDA's Susan Boc, titled "Explor- ing Aerosolized Powder Behav- ior in Dry Powder Inhalers using Advanced Imaging Techniques." Delegates who stayed until the end were rewarded with a thought-provoking "Explore with Experts" session on: "e MDI at 70: Evolving Science and Regula- tion." Industry (Tom Daly, Lucas Silva, Nick Smalley and Stephen Stein) and FDA representatives (Elizabeth Bielski, Bryan Newman and Markham Luke) collectively highlighted how new imaging and analytical tools could aid in assess- ment of bioequivalence (BE) and the transition to next generation propellants. Having foreshadowed this at RDD 2026, the FDA subse- quently announced updated Prod- uct Specific Guidances (PSGs) for metered dose inhalers (MDIs), making priming, spray pattern and plume geometry unneces- sary if Single Actuation Content and realistic aerodynamic particle size distribution studies were con- ducted as part of BE packages. Workshops, posters and corpo- rate exhibits greatly contributed to the success of RDD 2026, which also honored Anthony Hickey as the 2026 Charles G. iel Award winner, and saw the University of Alabama's Teri Ross presented with the 2026 VCU RDD Peter R. Byron Graduate Student Award for her work exploring how opti- cal photothermal infrared micros- copy could be used to characterize DPI blends.

Articles in this issue

Links on this page

view archives of Inhalation - INH1026